94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1532460
This article is part of the Research Topic Mechanisms and Therapeutic Opportunities of T Cell Impairment in Cancer Immunity and Immunotherapy View all 9 articles
Combination autologous stem cell transplantation with chimeric antigen receptor T-cell therapy for refractory/relapsed B-cell lymphoma: A single-arm clinical study
Provisionally accepted
Danyang Li 1* Rui Liu 1* Zhonghua Fu 1* Fan Yang 1* Lixia Ma 1* Yuelu Guo 1* Miaomiao Cao 1* Yang Lei 1* Yimeng Dou 1* Xuenan Zhang 1* Yan Gao 1* Bian Wei 1* Biping Deng 1* Xiaoyan Ke 1,2*
Kai Hu 1*- 1 Department of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, China
- 2 Department of Hematology, Peking University Third Hospital, Beijing, China
Autologous stem cell transplantation (ASCT) and chimeric antigen receptor T-cells (CAR-T) have been used as consolidation therapies for patients with refractory/recurrent B cell non-Hodgkin's lymphoma (R/R B-NHL) in remission after second-line chemotherapy or salvage therapy. However, patients with different pathological subtypes and remission states may benefit differently from ASCT or CAR-T cell therapy. Furthermore, consolidation treatment involving ASCT or CAR-T cells still poses a significant risk of disease relapse. We conducted a retrospective, single-arm study of 47 patients with R/R B-NHL, and found that the combination of ASCT and CAR-T therapy improved the 3-year progression-free survival (PFS) and overall survival (OS) rates to 66.04% (95%CI: 48.311-78.928) and 72.442% (95%CI: 53.46-84.708) respectively. Furthermore, the combination therapy has no serious adverse events. Thus, ASCT combined with CAR-T cell therapy is effective against multiple subtypes of R/R B-NHL, and can effectively prolong the long-term survival of patients.
Keywords: B-NHL, car-t, ASCT, combination therapy, refractory/relapsed B-cell lymphoma
Received: 22 Nov 2024; Accepted: 10 Feb 2025.
Copyright: © 2025 Li, Liu, Fu, Yang, Ma, Guo, Cao, Lei, Dou, Zhang, Gao, Wei, Deng, Ke and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Danyang Li, Department of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, China
Rui Liu, Department of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, China
Zhonghua Fu, Department of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, China
Fan Yang, Department of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, China
Lixia Ma, Department of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, China
Yuelu Guo, Department of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, China
Miaomiao Cao, Department of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, China
Yang Lei, Department of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, China
Yimeng Dou, Department of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, China
Xuenan Zhang, Department of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, China
Yan Gao, Department of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, China
Bian Wei, Department of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, China
Biping Deng, Department of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, China
Xiaoyan Ke, Department of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, China
Kai Hu, Department of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.